Market forces or forcing the market
What are the current challenges and future opportunities for opening up the ATMP markets? MHRA, NICE and NHS England are working together can make the UK attractive, but there are lower number of patients in UK as opposed to Europe. So how attractive is the UK for investment? How can investors get quicker and better returns? Is there a divergence from MHRA and EMA?
FACILITATED BY
NATHAN SIGWORTH | Co-founder and Chief Executive Officer | PharmaCCX
PANELLISTS INCLUDE
CAROLE LONGSON | Independent Senior Advisor | Life Science Policy, HTA and Market Access
ROUDIE SHAFIE | Director | OVID Health
ALASTAIR THONG | Founder | Selvedge Venture
GAVIN LEWIS | Vice President, Global Value and Access | Amgen (Europe) GmbH